Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)
Conditions
Interventions
Tolebrutinib
Placebo
Locations
277
United States
UC San Diego ACTRI Site Number : 8400101
La Jolla, California, United States
Collaborative Neuroscience Research Site Number : 8400045
Los Alamitos, California, United States
Multiple Sclerosis Center- Site Number : 8400143
Los Angeles, California, United States
Multiple Sclerosis Center of California Site Number : 8400135
Newport Beach, California, United States
SC3 Research - Pasadena Site Number : 8400070
Pasadena, California, United States
University of San Francisco, Sandler Neurosciences Center- Site Number : 8400137
San Francisco, California, United States
Start Date
August 13, 2020
Primary Completion Date
November 14, 2025
Completion Date
November 14, 2025
Last Updated
January 7, 2026
NCT07426991
NCT05893225
NCT04943289
NCT05349474
NCT06677710
NCT06900192
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions